Leerink Partnrs Has Positive Estimate for IDXX Q2 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for IDEXX Laboratories in a research note issued on Thursday, July 17th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $3.31 per share for the quarter, up from their previous forecast of $3.22. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories' Q3 2025 earnings at $3.13 EPS, Q4 2025 earnings at $2.91 EPS, FY2025 earnings at $12.31 EPS, FY2026 earnings at $13.89 EPS, FY2027 earnings at $15.65 EPS and FY2028 earnings at $17.47 EPS.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same quarter last year, the firm posted $2.71 EPS. The firm's revenue was up 3.6% compared to the same quarter last year.

Other analysts have also issued reports about the stock. Stifel Nicolaus boosted their price objective on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a report on Wednesday, July 2nd. Morgan Stanley increased their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $560.33.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $520.55 on Friday. IDEXX Laboratories has a 1 year low of $356.14 and a 1 year high of $549.52. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The company's fifty day moving average price is $523.12 and its 200 day moving average price is $462.00. The stock has a market capitalization of $41.86 billion, a P/E ratio of 48.18, a P/E/G ratio of 3.80 and a beta of 1.54.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp lifted its holdings in shares of IDEXX Laboratories by 13.1% in the fourth quarter. Cibc World Markets Corp now owns 14,744 shares of the company's stock valued at $6,096,000 after purchasing an additional 1,709 shares in the last quarter. Horizon Investments LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% in the fourth quarter. Horizon Investments LLC now owns 1,296 shares of the company's stock valued at $536,000 after purchasing an additional 42 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of IDEXX Laboratories by 165.2% in the fourth quarter. Intech Investment Management LLC now owns 6,421 shares of the company's stock valued at $2,655,000 after purchasing an additional 4,000 shares in the last quarter. Harvest Fund Management Co. Ltd lifted its holdings in shares of IDEXX Laboratories by 27.1% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 4,819 shares of the company's stock valued at $1,947,000 after purchasing an additional 1,028 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 18.6% in the fourth quarter. iA Global Asset Management Inc. now owns 13,763 shares of the company's stock valued at $5,690,000 after purchasing an additional 2,158 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.